By fostering a favorable microbial environment rich in SCFA‐producing taxa and reducing the prevalence of pro‐inflammatory genera, BL21 may indirectly enhance gut barrier function, attenuate chronic low‐grade inflammation, and improve insulin signaling pathways, ultimately contributing to better glycemic control in patients with T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.